L’Oreal has strategically expanded its presence into the medical aesthetics sector by acquiring stakes in clinics across China and North America, according to CEO Nicolas Hieronimus during a recent earnings call.
In August, the cosmetic giant revealed the acquisition of a 10% stake in Galderma, a prominent Swiss skincare company. This move aligns with LOreal’s broader strategy to comprehend the dynamics of the medical aesthetics market, which has been showing robust growth. According to data provided by IndexBox, the global market for medical aesthetics is projected to reach significant figures, driven by rising consumer demand and advancements in technologies.
Apart from its ventures into medical aesthetics, Hieronimus shared that LOreal plans to make a foray into the nutricosmetics market by launching an innovative new product, suggesting that more exciting developments are on the horizon.
